These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25845536)

  • 1. Replicating poxviruses for human cancer therapy.
    Kim M
    J Microbiol; 2015 Apr; 53(4):209-18. PubMed ID: 25845536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring reoviruses for human cancer therapy.
    Kim M
    BMB Rep; 2015 Aug; 48(8):454-60. PubMed ID: 26058397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.
    Kim M; Williamson CT; Prudhomme J; Bebb DG; Riabowol K; Lee PW; Lees-Miller SP; Mori Y; Rahman MM; McFadden G; Johnston RN
    Oncogene; 2010 Jul; 29(27):3990-6. PubMed ID: 20473328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
    Kirn DH; Thorne SH
    Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
    Breitbach CJ; Thorne SH; Bell JC; Kirn DH
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
    Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.
    Stanford MM; McFadden G
    Expert Opin Biol Ther; 2007 Sep; 7(9):1415-25. PubMed ID: 17727330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
    Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
    Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replicating viruses for gynecologic cancer therapy.
    Park JW; Kim M
    Eur J Gynaecol Oncol; 2016; 37(3):295-304. PubMed ID: 27352554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
    Stanford MM; Barrett JW; Nazarian SH; Werden S; McFadden G
    J Virol; 2007 Feb; 81(3):1251-60. PubMed ID: 17108021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Oncolytic Poxviruses: An Emerging Paradigm in Cancer Therapy.
    Chakraborty P; Kumar R; Karn S; Raviya DD; Mondal P
    Adv Exp Med Biol; 2024; 1451():369-381. PubMed ID: 38801591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poxvirus oncolytic virotherapy.
    Torres-Domínguez LE; McFadden G
    Expert Opin Biol Ther; 2019 Jun; 19(6):561-573. PubMed ID: 30919708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells.
    Rahman MM; Gutierrez-Jensen AD; Glenn HL; Abrantes M; Moussatche N; McFadden G
    J Virol; 2021 Jun; 95(14):e0015121. PubMed ID: 33952639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
    Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
    Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Poxviruses.
    Chan WM; McFadden G
    Annu Rev Virol; 2014 Sep; 1(1):119-141. PubMed ID: 25839047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus.
    Werden SJ; McFadden G
    Biochim Biophys Acta; 2008 Jan; 1784(1):228-37. PubMed ID: 17905673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.
    Chen NG; Yu YA; Zhang Q; Szalay AA
    J Transl Med; 2011 Sep; 9():164. PubMed ID: 21951588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase.
    Hu W; Hofstetter W; Guo W; Li H; Pataer A; Peng HH; Guo ZS; Bartlett DL; Lin A; Swisher SG; Fang B
    Cancer Gene Ther; 2008 Sep; 15(9):616-24. PubMed ID: 18535619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
    Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
    Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.